Drug Profile
MDNA 132
Alternative Names: MDNA - 132Latest Information Update: 26 May 2023
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Medicenna Therapeutics
- Class Antineoplastics; Cytokines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Interleukin 13 receptor alpha2 subunit modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 Oct 2022 MDNA 132 is still in preclinical development for Solid-tumours in Canada
- 28 Apr 2021 No recent reports of development identified for preclinical development in Solid-tumours in Canada